Protein | Primary tumors | Metastatic tumors | Sign test, P value |
---|
| 0 | 1 | 2 | 0 | 1 | 2 | |
---|
pHER1 | 25 | -- | 5 | 11 | -- | 19 |
0.0003
|
pHER2 | 17 | 5 | 7 | 14 | 10 | 6 | 0.6072 |
pHER3 | 23 | -- | 5 | 16 | -- | 13 |
0.0034
|
Nuclear pHER3 | 27 | -- | 1 | 15 | -- | 14 |
0.0002
|
HER4 | -- | 13 | 17 | -- | 19 | 10 | 0.1435 |
Cytoplasmic pErk | 10 | 4 | 15 | 6 | 12 | 12 | 1.0000 |
Nuclear pErk | 10 | 3 | 16 | 6 | 6 | 18 | 0.4545 |
Cytoplasmic pAkt | 3 | 19 | 8 | 10 | 5 | 14 | 0.8036 |
Nuclear pAkt | 16 | 8 | 8 | 10 | 7 | 12 | 0.0768 |
- Category 0 = number of negative cases, category 1 = number of weak-expressing (pHER2), low-expressing (HER4) or moderate-expressing (pErk and pAkt) cases, and category 2 = number of positive (pHER1 and pHER3) or strong-expressing (pHER2, pErk and pAkt) cases. Expression of pHER1, pHER3 and nuclear pHER3 was analyzed as negative or positive, hence '--' in category 1. HER4 expression was evaluated as either low or high, hence '--' in category 0. The Sign test was used to examine for significant differences in protein expression levels between primary and metastatic tumors. Bold data represent significant values.